+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The role of matrix metalloproteinases and cardiac fibroblasts in heart failure progression



The role of matrix metalloproteinases and cardiac fibroblasts in heart failure progression



European Heart Journal 24(Abstract Suppl.): 656, August-September




(PDF emailed within 1 workday: $29.90)

Accession: 035928903

Download citation: RISBibTeXText


Related references

Cardiac matrix remodelling in congestive heart failure: the role of matrix metalloproteinases. Clinical and Investigative Medicine. Medecine Clinique et Experimentale 27(2): 93-100, 2004

Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications. Drugs 61(9): 1239-1252, 2001

Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. Journal of the American College of Cardiology 42(2): 336-344, July 16, 2003

Matrix metalloproteinases and their tissue inhibitors in pressure-overloaded human myocardium during heart failure progression. Journal of the American College of Cardiology 44(8): 1609-1618, 2004

Inhibition of matrix metalloproteinases An additional effect of ACE inhibitors on cardiac remodelling in heart failure?. European Heart Journal 21(Abstract Suppl.): 465, August-September, 2000

Dynamic role of extracellular matrix metalloproteinases in heart failure. Cardiovascular Pathology 7(3): 153-159, 1998

The gp130 ligand oncostatin M regulates tissue inhibitor of metalloproteinases-1 through ERK1/2 and p38 in human adult cardiac myocytes and in human adult cardiac fibroblasts: a possible role for the gp130/gp130 ligand system in the modulation of extracellular matrix degradation in the human heart. Journal of Molecular and Cellular Cardiology 39(3): 545-551, 2005

Matrix metalloproteinases, tissue inhibitors of metalloproteinases, and heart failure outcomes. International Journal of Cardiology 151(2): 237-239, 2012

Effects of chronic therapy with cardiac contractility modulation electrical signals on cytoskeletal proteins and matrix metalloproteinases in dogs with heart failure. Cardiology 110(4): 230-237, 2007

Polymorphisms of matrix metalloproteinases in systolic heart failure: role on disease susceptibility, phenotypic characteristics, and prognosis. Journal of Cardiac Failure 17(2): 115-121, 2011

The expression of matrix metalloproteinases in intrahepatic cholangiocarcinoma, hilar (Klatskin tumor), middle and distal extrahepatic cholangiocarcinoma, gallbladder cancer, and ampullary carcinoma: role of matrix metalloproteinases in tumor progression and prognosis. Turkish Journal of Gastroenterology 20(1): 41-47, 2009

Treatment with spironolactone for 24 weeks decreases the level of matrix metalloproteinases and improves cardiac function in patients with chronic heart failure of ischemic etiology. Canadian Journal of Cardiology 25(9): 523-526, 2009

Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure. International Journal of Cardiology 145(3): 438-443, 2011

Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases levels in pediatric patients with congenital heart disease: Relationship to cardiac functions. Anadolu Kardiyoloji Dergisi 14(6): 531-541, 2016

Role of matrix metalloproteinases and their tissue inhibitor of metalloproteinases in myxomatous change of cardiac floppy valves. Pathology International 57(5): 251-259, 2007